Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Mallinckrodt
McKesson
Dow
AstraZeneca
Teva
Johnson and Johnson
QuintilesIMS

Generated: May 21, 2018

DrugPatentWatch Database Preview

BICALUTAMIDE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Bicalutamide patents expire, and when can generic versions of Bicalutamide launch?

Bicalutamide is a drug marketed by Accord Hlthcare, Apotex Inc, Fresenius Kabi Oncol, Kudco Ireland, Mylan, Roxane, Sandoz, Santos Biotech, Sun Pharma Global, Synthon Pharms, Teva, Watson Labs Teva, and Zydus Pharms Usa Inc. and is included in thirteen NDAs.

The generic ingredient in BICALUTAMIDE is bicalutamide. There are twenty-nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the bicalutamide profile page.
Drug patent expirations by year for BICALUTAMIDE
Synonyms for BICALUTAMIDE
(+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide
357B065
4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide
4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide
4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide
90357-06-5
A803039
AB0008136
AB00639963_10
AB00639963-06
AB00639963-08
AB00639963-09
AC-4232
AC1L1DJE
ACT06291
AKOS015895073
AN-582
AOB5596
API0001710
Astra brand of bicalutamide
AstraZeneca brand of bicalutamide
AT-9158
B3206
BC204097
BCP9000408
BCPP000337
BDBM18525
bicalutamida
Bicalutamide - Casodex
Bicalutamide (Casodex)
Bicalutamide (CDX)
Bicalutamide (CDX), >=98% (HPLC), powder
Bicalutamide (JAN/USP/INN)
Bicalutamide [USAN:INN:BAN]
Bicalutamide [USAN:USP:INN:BAN]
Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard
Bicalutamide, European Pharmacopoeia (EP) Reference Standard
Bicalutamide, pharmaceutical secondary standard; traceable to USP, PhEur, BP
Bicalutamide, United States Pharmacopeia (USP) Reference Standard
Bicalutamide(Casodex)
bicalutamidum
Bicalutamine
BRN 5364666
C08160
C18H14F4N2O4S
Calutide
Calutide (TN)
Casodex
Casodex (TN)
Casodex, Cosudex, Calutide, Kalumid, Bicalutamide
CB0180
CCG-100951
CCG-220876
CCG-222330
CCRIS 8728
CHEBI:91617
CHEMBL409
Cosudex
Cosudex (TN)
CPD000466329
CS-1296
D00961
D0V9BD
DB01128
DR002659
DTXSID2022678
EX-A962
FT-0080576
FT-0618286
GTPL2863
HMS2051B13
HMS2089N12
HMS2232H03
HMS3263M13
HMS3372K05
HMS3393B13
HMS3654K18
HSDB 7655
HY-14249
I06-0475
I06-0480
ICI 176,334
ICI 176334
ICI-176334
J10442
Kalumid
Kalumid (TN)
KS-00000XEI
KS-1161
LKJPYSCBVHEWIU-UHFFFAOYSA-N
LP01026
LS-119125
MFCD00869971
MLS000759437
MLS001424047
MolPort-003-845-034
MolPort-006-808-679
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide
N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide
NC00201
NCGC00167977-01
NCGC00167977-02
NCGC00167977-03
NCGC00261711-01
NSC-722665
NSC-759816
NSC722665
NSC759816
OR108998
Pharmakon1600-01504827
PRO113
Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-
Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-
propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-)
PubChem18237
Raffolutil
s1190
SAM001246612
SC-17332
SCHEMBL3611
SMR000466329
SR-01000759410
SR-01000759410-4
TL8005814
Tox21_501026
Zeneca brand of bicalutamide

US Patents and Regulatory Information for BICALUTAMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare BICALUTAMIDE bicalutamide TABLET;ORAL 078917-001 Jul 6, 2009 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sandoz BICALUTAMIDE bicalutamide TABLET;ORAL 078575-001 Jul 6, 2009 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Kudco Ireland BICALUTAMIDE bicalutamide TABLET;ORAL 077995-001 Jul 6, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Watson Labs Teva BICALUTAMIDE bicalutamide TABLET;ORAL 078634-001 Aug 28, 2009 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
US Department of Justice
Accenture
Teva
Moodys
Deloitte
McKesson
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.